@article {8327,
	title = {Somatic, hematologic phenotype, long-term outcome, and effect of hematopoietic stem cell transplantation. An analysis of 97 Fanconi anemia patients from the Italian national database on behalf of the Marrow Failure Study Group of the AIEOP (Italian Associ},
	journal = {Am J Hematol},
	volume = {91},
	year = {2016},
	month = {2016 Jul},
	pages = {666-71},
	abstract = {<p>We analyzed 97 Fanconi anemia patients from a clinic/biological database for genotype, somatic, and hematologic phenotype, adverse hematological events, solid tumors, and treatment. Seventy-two patients belonged to complementation group A. Eighty percent of patients presented with mild/moderate somatic phenotype and most with cytopenia. No correlation was seen between somatic/hematologic phenotype and number of missense mutations of FANCA alleles. Over follow-up, 33\% of patients improved or maintained mild/moderate cytopenia or normal blood count, whereas remaining worsened cytopenia. Eleven patients developed a hematological adverse event (MDS, AML, pathological cytogenetics) and three developed solid tumors. 10 years cumulative risk of death of the whole cohort was 25.6\% with median follow-up 5.8 years. In patients eligible to hematopoietic stem cell transplantation because of moderate cytopenia, mortality was significantly higher in subjects transplanted from matched unrelated donor over nontransplanted subjects, whereas there was no significant difference between matched sibling donor transplants and nontransplanted patients. In patients eligible to transplant because of severe cytopenia and clonal disease, mortality risk was not significantly different in transplanted from matched unrelated versus matched sibling donor versus nontransplanted subjects. The decision to transplant should rely on various elements including, type of donor, HLA matching, patient comorbidities, impairment, and clonal evolution of hematopoiesis. Am. J. Hematol. 91:666-671, 2016. {\textcopyright} 2016 Wiley Periodicals, Inc.</p>},
	issn = {1096-8652},
	doi = {10.1002/ajh.24373},
	author = {Svahn, Johanna and Bagnasco, Francesca and Cappelli, Enrico and Onofrillo, Daniela and Caruso, Silvia and Corsolini, Fabio and De Rocco, Daniela and Savoia, Anna and Longoni, Daniela and Pillon, Marta and Marra, Nicoletta and Ramenghi, Ugo and Farruggia, Piero and Locasciulli, Anna and Addari, Carmen and Cerri, Carla and Mastrodicasa, Elena and Casazza, Gabriella and Verzegnassi, Federico and Riccardi, Francesca and Haupt, Riccardo and Barone, Angelica and Cesaro, Simone and Cugno, Chiara and Dufour, Carlo}
}
@article {3552,
	title = {Spectrum of the mutations in Bernard-Soulier syndrome.},
	journal = {Hum Mutat},
	volume = {35},
	year = {2014},
	month = {2014 Sep},
	pages = {1033-45},
	abstract = {<p>Bernard-Soulier syndrome (BSS) is a rare autosomal recessive bleeding disorder characterized by defects of the GPIb-IX-V complex, a platelet receptor for von Willebrand factor (VWF). Most of the mutations identified in the genes encoding for the GP1BA (GPIbα), GP1BB (GPIbβ), and GP9 (GPIX) subunits prevent expression of the complex at the platelet membrane or more rarely its interaction with VWF. As a consequence, platelets are unable to adhere to the vascular subendothelium and agglutinate in response to ristocetin. In order to collect information on BSS patients, we established an International Consortium for the study of BSS, allowing us to enrol and genotype 132 families (56 previously unreported). With 79 additional families for which molecular data were gleaned from the literature, the 211 families characterized so far have mutations in the GP1BA (28\%), GP1BB (28\%), or GP9 (44\%) genes. There is a wide spectrum of mutations with 112 different variants, including 22 novel alterations. Consistent with the rarity of the disease, 85\% of the probands carry homozygous mutations with evidence of founder effects in some geographical areas. This overview provides the first global picture of the molecular basis of BSS and will lead to improve patient diagnosis and management.</p>},
	keywords = {Alleles, Bernard-Soulier Syndrome, Databases, Nucleic Acid, Founder Effect, Genetic Variation, Humans, Mutation, Platelet Glycoprotein GPIb-IX Complex, Polymorphism, Single Nucleotide, von Willebrand Diseases, Web Browser},
	issn = {1098-1004},
	doi = {10.1002/humu.22607},
	author = {Savoia, Anna and Kunishima, Shinji and De Rocco, Daniela and Zieger, Barbara and Rand, Margaret L and Pujol-Moix, N{\'u}ria and Caliskan, Umran and Tokgoz, Huseyin and Pecci, Alessandro and Noris, Patrizia and Srivastava, Alok and Ward, Christopher and Morel-Kopp, Marie-Christine and Alessi, Marie-Christine and Bellucci, Sylvia and Beurrier, Philippe and de Maistre, Emmanuel and Favier, R{\'e}mi and H{\'e}zard, Nathalie and Hurtaud-Roux, Marie-Fran{\c c}oise and Latger-Cannard, V{\'e}ronique and Lavenu-Bombled, C{\'e}cile and Proulle, Val{\'e}rie and Meunier, Sandrine and N{\'e}grier, Claude and Nurden, Alan and Randrianaivo, Hanitra and Fabris, Fabrizio and Platokouki, Helen and Rosenberg, Nurit and HadjKacem, Basma and Heller, Paula G and Karimi, Mehran and Balduini, Carlo L and Pastore, Annalisa and Lanza, Francois}
}
